BAVA Bavarian Nordic A/S

Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with such

Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with such

COPENHAGEN, Denmark, September 10, 2021 – Bavarian Nordic A/S (OMX: BAVA) has today received information about the following transactions of the company’s shares/related securities by persons holding managerial responsibilities and/or persons/companies closely associated with such.

1.Details of the person discharging managerial responsibilities/person closely associated  
a)NameHenrik Birk
2.Reason for the notification
a)Position/statusExecutive Vice President and Chief Operating Officer of Bavarian Nordic A/S
b)Initial notification/AmendmentInitial notification
3.Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)NameBavarian Nordic A/S
b)LEI2138006JCDVYIN6INP51
4.Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)Description of the financial instrument, type of instrument





Identification code
Shares





DK0015998017
b)Nature of the transactionExercise of warrants
c)Price(s) and volume(s)Price(s)Volume(s)
  DKK 205.805,000
  DKK 239.6014,518
d)Aggregated information
  • Aggregated volume
  • Price
 



19,518

DKK 4.507.512,80
e)Date of the transaction2021-09-08
f)Place of the transactionNasdaq Copenhagen A/S, XCSE



1.Details of the person discharging managerial responsibilities/person closely associated  
a)NameHenrik Birk
2.Reason for the notification
a)Position/statusExecutive Vice President and Chief Operating Officer of Bavarian Nordic A/S
b)Initial notification/AmendmentInitial notification
3.Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)NameBavarian Nordic A/S
b)LEI2138006JCDVYIN6INP51
4.Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)Description of the financial instrument, type of instrument





Identification code
Shares





DK0015998017
b)Nature of the transactionSale
c)Price(s) and volume(s)Price(s)Volume(s)
  DKK 345.2819,518
d)Aggregated information
  • Aggregated volume
  • Price
 



19,518

DKK 6,739,223.10
e)Date of the transaction2021-09-10
f)Place of the transactionNasdaq Copenhagen A/S, XCSE

About Bavarian Nordic

Bavarian Nordic is a fully integrated vaccines company focused on the development, manufacturing and commercialization of life-saving vaccines. We are a global leader in smallpox vaccines and have been a long-term supplier to the U.S. Government of a non-replicating smallpox vaccine, which has been approved by the FDA, also for the protection against monkeypox. The vaccine is approved as a smallpox vaccine in Europe and Canada. Our commercial product portfolio furthermore contains market-leading vaccines against rabies and tick-borne encephalitis. Using our live virus vaccine platform technology, MVA-BN®, we have created a diverse portfolio of proprietary and partnered product candidates designed to save and improve lives by unlocking the power of the immune system, including an Ebola vaccine, which is licensed to the Janssen Pharmaceutical Companies of Johnson & Johnson. We are also committed to the development of a next generation COVID-19 vaccine. For more information visit .

Contacts

Europe: Rolf Sass Sørensen, Vice President Investor Relations, Tel:

US: Graham Morrell, Paddock Circle Advisors, , Tel:

Company Announcement no. 31 / 2021

Attachment



EN
10/09/2021

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Bavarian Nordic A/S

 PRESS RELEASE

Bavarian Nordic offentliggør storaktionærmeddelelse fra Morgan Stanley

Bavarian Nordic offentliggør storaktionærmeddelelse fra Morgan Stanley KØBENHAVN, Danmark, 31. oktober 2025 – I henhold til §30 i Lov om kapitalmarkeder, meddeler Bavarian Nordic A/S hermed, at selskabet har modtaget meddelelse fra Morgan Stanley om, at de pr. 27. oktober 2025 besidder 4.99% af aktierne og stemmerettighederne i Bavarian Nordic A/S. Om Bavarian NordicBavarian Nordic er et globalt vaccineselskab med en mission om at forbedre sundheden og redde liv gennem innovative vacciner. Vi er en foretrukken leverandør af mpox- og koppevacciner til regeringer med hensyn til at forbedre ...

 PRESS RELEASE

Bavarian Nordic Announces Major Shareholder Notification from Morgan S...

Bavarian Nordic Announces Major Shareholder Notification from Morgan Stanley COPENHAGEN, Denmark, October 31, 2025 – Pursuant to section 30 of the Danish Capital Markets Act, Bavarian Nordic A/S hereby announces that the Company has received notification from Morgan Stanley that they hold 4.99% of the shares and voting rights in Bavarian Nordic A/S as of October 27, 2025. About Bavarian NordicBavarian Nordic is a global vaccine company with a mission to improve health and save lives through innovative vaccines. We are a preferred supplier of mpox and smallpox vaccines to governments to en...

 PRESS RELEASE

Bavarian Nordic aktionærer påmindes om udløbet af tilbudsperioden vedr...

Bavarian Nordic aktionærer påmindes om udløbet af tilbudsperioden vedrørende overtagelsestilbuddet fra konsortium bestående af Nordic Capital og Permira MÅ IKKE UDGIVES, OFFENTLIGGØRES ELLER DISTRIBUERES, DIREKTE ELLER INDIREKTE, I ELLER TIL NOGEN JURISDIKTION, HVOR DETTE VILLE UDGØRE EN OVERTRÆDELSE AF DE RELEVANTE LOVE ELLER FORORDNINGER I DEN PÅGÆLDENDE JURISDIKTION København, Danmark, 31 oktober, 2025 – Der henvises til selskabsmeddelelserne af 26. august 2025 (nr. 24/2025), 29. september 2025 (nr. 27/2025), 15. oktober 2025 (nr. 31/2025) og 21. oktober 2025 (nr. 33/2025) vedrørende de...

 PRESS RELEASE

Bavarian Nordic shareholders are reminded of expiry of the offer perio...

Bavarian Nordic shareholders are reminded of expiry of the offer period regarding the takeover offer from consortium consisting of Nordic Capital and Permira NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION COPENHAGEN, Denmark, 31 October, 2025 – Reference is made to the company announcements dated 26 August 2025 (no. 24/2025), 29 September 2025 (no. 27/2025), 15 October 2025 (no. 31/2025), and 21 October 2025 (no. 33/2025) regarding the all-c...

 PRESS RELEASE

Bavarian Nordic opnår ny rammeaftale med Europa-Kommissionen med henbl...

Bavarian Nordic opnår ny rammeaftale med Europa-Kommissionen med henblik på styrkelse af beredskabet mod kopper og mpox Ny og større rammeaftale med Europa-Kommissionens Myndighed for Kriseberedskab og ‑indsats på Sundhedsområdet (HERA) erstatter tidligere aftale og omfatter op til 8 millioner doser af koppe-/mpoxvaccinen over de næste fire år.Yderligere lande har tiltrådt aftalen, som nu giver adgang til vaccinen for 20 EU-medlemslande og andre europæiske lande. KØBENHAVN, Danmark, 31. oktober 2025 – Bavarian Nordic A/S (OMX: BAVA) meddelte i dag, at selskabet har fået tildelt en fælles ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch